

Date: _____

To Whom It May Concern:

Please be advised that the Dana-Farber Cancer Institute operates in full compliance with all DHHS, FDA and Massachusetts regulations governing the use of human subjects in research. DFCI has a Federal Wide Assurance (FWA) on file with the Office for Human Research Protections (OHRP) and our institutional review boards (IRBs) are registered with OHRP as well.

FWA# 00001121 expires August 14, 2012

IRB registration numbers: 0000052, 00000753, 00001186, 00003340, 00005504, 00006224

IORG# 0000035 expires on August 5, 2012

Agreements between the Dana-Farber Cancer Institute (DFCI), Brigham and Women's Hospital (BWH), Massachusetts General Hospital (MGH), Beth Israel Deaconess Medical Center (BIDMC), Children's Hospital of Boston (CHB) and several affiliate institutions allow the DFCI IRBs to serve as IRB of record for specific oncology trials.

The attached IRB Approval covers the following checked institution(s):

Protocol _____ Principal Investigator _____

- | | | | |
|---|--|---------------------|-----------------------|
| <input type="checkbox"/> DFCI #<u>MA036</u> | <input type="checkbox"/> Cape Cod HealthCare | INST#: <u>MA078</u> | FWA#: <u>00001747</u> |
| <input type="checkbox"/> BWH #<u>MA037</u> | <input type="checkbox"/> Lowell General Hosp. | INST#: <u>MA134</u> | FWA#: <u>00001027</u> |
| <input type="checkbox"/> MGH # <u>MA034</u> | <input type="checkbox"/> N.H. Onc-Hematology | INST#: <u>NH015</u> | FWA#: <u>00004392</u> |
| <input type="checkbox"/> BIDMC #<u>MA038</u> | <input type="checkbox"/> South Shore Hospital | INST#: <u>MA087</u> | FWA#: <u>00005520</u> |
| <input type="checkbox"/> CHB #<u>MA04</u> | | | |

- | | | |
|--------------------------------|--------------|-------------|
| <input type="checkbox"/> _____ | INST#: _____ | FWA#: _____ |
| <input type="checkbox"/> _____ | INST#: _____ | FWA#: _____ |
| <input type="checkbox"/> _____ | INST#: _____ | FWA#: _____ |

The DFCI IRB does not post its IRB rosters nor do we release names of IRB members. However, any IRB member who is an investigator, co-investigator or has any other conflict of interest with a protocol under review by the IRB will not participate in the vote of that protocol although he or she may be called upon to answer questions during the review.

The DFCI IRB does not require its IRB Chairs or any other member of the IRB to sign approval documents. There is no regulatory requirement for such signatures. These documents are generated by the staff of the Office for Human Research Studies (OHRS), which is the office that manages scientific and IRB review for both the Dana-Farber Cancer Institute and the Dana-Farber/Harvard Cancer Center. If you require additional information please contact our office at the number listed above. (Please note: OHRS was formerly the Office for the Protection of Research Subjects. The change in name occurred in September of 2008.)

Sincerely,



Michele Russell-Einhorn, JD
 Director